The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Feels pretty good so far, up at 105p, and threatening 110p on a few occasions. Hopefully on a slow drift back into the 120s!
We are in at the same price.....Lets see what happens over the next few weeks.
Very small effective free float, so even small buyers and sellers can move the price a lot with no real news. Can provide a bit of excitement/concern from time to time, but certainly does provide some great buying opportunities - I was fortunate enough to get in yesterday morning at 92p, but I certainly wouldn't bet against it going back down there again at some point, (when I'll buy some more!!). GLA
but cannot see any recent news. Bought in earlier in the week as I like the multi-pronged approach of this company and I think the salmon business has great potential. gla
Absolutely - this is a little gem waiting to be discovered. With a rising global population aquaculture (basically fish pharma) is going to become a huge growth area. Bmk is positioning itself beautifully in this niche mkt currently, but with fantastic LT growth potential.
an interesting diversified little company. With Invesco/Woodford having some 30pct of the shares and another 40pct in the hands of institutional and other supporters, I believe the limited share availability will cause this share to move quickly when it becomes better known. Hope so as I bought in today....
If you would like to hear Benchmark discuss their full year results we will be hosting a webinar with company management on the 28th of January at 2.30pm. They will give a 25 minute presentation with an opportunity for Q&A at the end. If you would like to participate, please register now: https://attendee.gotowebinar.com/register/6642754838648852993 After registering, you will receive a confirmation email containing information about joining the webinar. If you would like to submit any questions for management ahead of the meeting please send them to hannah@equitydevelopment.co.uk. Thanks, The Equity Development Team
in holding, no SP change.
Hi, Our new note on Benchmark is available on our website: www.equitydevelopment.co.uk Registration is free. Thanks, The Equity Development team
Up 6%
Monday will be interesting
"Benchmark Holdings PLC, the international animal health, technical publishing and sustainability science business, announces that its Animal Health division has entered into an agreement with HypoPet AG ("HypoPet"), a Swiss research company based at the University of Zurich, for the final commercialisation, manufacture and distribution of a breakthrough vaccine for cats, HypoCat®, which neutralises the Fel d 1 protein, the primary cause of human allergic reaction to cats. With an estimated 10% of the global population suffering from cat allergies, the agreement between HypoPet and Benchmark is designed to open up a new market within the animal health sector with an estimated global value of £250 million. Benchmark's world-class vaccine manufacturing facilities in Braintree and Edinburgh, combined with its proven vaccine and process development experience puts it in an ideal position to develop and commercialise this innovative new vaccine."
I agree. This has been on my watchlist for a while but I am wondering why there are so few people commenting on it.
sounds good
It seems that Mr Woodford has bought 6.2% of the company. Which might move the share price north a little and get some recognition for the shares on the markets.
This company does a whole lot more than making animal vaccines and publishing books.. the publishing arm is in Chicago, they develop vaccines yes on behalf of companies like Novartis and MSD as well as their own brands, they are heavily involved with FMCG companies worldwide and extensively with conglomerate brands that feature in all your daily lives wherever you go, they have businesses in the UK, China, Brazil, USA etc.. their knowledge is a thought process outside the box, they are creating the future of the food supply chain, something that is played down all around us daily but food doesnt come from supermarkets.. it comes from farms.. this is certainly a quality company to be buying into.. (I'll be topping up shortly too).. Everything BMK does is based around a principle of the 3E's - Environment, Economics & Ethics for sustainability http://www.faifarms.com/our-farms-offices and http://5mpublishing.com/ and http://fishvetgroup.com/ this is NOT about GM, this is all natural science thought differently
Well the IPO price was around 70p, so 100p looks like a good price to buy.
THE transaction services team at BDO has successfully advised an animal health, technical publishing and sustainability science business on its flotation on the Alternative Investment Market. In an oversubscribed fundraising led by Cenkos Securities and supported by Equity Development, Sheffield-based Benchmark Holdings successfully raised £27.5m before expenses through the sale of new ordinary shares at a price of 64p each to a diverse range of investors. In addition, existing shareholders sold shares worth £17.6m. Total gross proceeds from the placing amounted to £45.1m, making this the largest fundraising in the healthcare sector on AIM during 2013. Based on the placing price, Benchmark Holdings had a market capitalisation of approximately £87.3m on admission to AIM. The proceeds of the fundraising will be used by Benchmark to invest in high quality scientific research and development, to enhance its business development team, to expand its core businesses and enter into new segments which fit synergistically with its existing businesses. The proceeds will also be used to fund the expansion of Benchmark’s manufacturing base, as well as selective acquisitions. Malcolm Pye, chief executive officer, Benchmark, said: “We are really pleased that Benchmark has been so well received. The quality and breadth of our new shareholder base is evidence to the confidence people have in our company. “Our goal has always been to become a world leading specialist in the development of a sustainable food chain with a particular focus on the development of aquaculture health. The AIM market will provide Benchmark with access to capital and tradable equity, enabling us to pursue a strong pipeline of potential new products and technologies and continue to build the group by acquisition. The team and I are looking forward to this exciting new chapter in Benchmark’s development.”
Interesting company, seem unable to market themselves to the share market. Even today's aquisition has been under played. This sometimes happens with scientific based companies who don't really understand being a public company and just see it as a way to get cheaper funding. Once the main shareholders want to exit they will have to hire in a marketing team to make a noise. Assuming the staff are on 12 to 18 month restrictions they will start getting interested in about 6 months time. I'd just put away for 6 months
Thank you
The company makes vaccines for animals,publishes books & provides advice on animal health. I was in here for a few weeks & lost patience with the share not doing a great deal. There a great company,making profits with high profit margins,allot of potential. But they have quite a large market cap,around 175Mil,so will take quite a bit of money too move them in the right direction. Why not check out TYRU,they look a better bet,small cap,around (6 mil),will start selling there products around April in walmart.
I keep looking at this company but I can't really understand exactly what it does and why it should flourish. I have a gut feeling that it may do very well, but hesitate to invest until I can convert that gut feeling into something more rational.
Gone very quiet on this stock, any reason? It seems to be holding up ok
Looks like we are on the next move up,buying price going back up.
Not sure why this company has been so overlooked by private investors. We have a profit making company with high profit margins. They keep expanding & buying up other companies. They will not need too issue new shares in order too keep going,due too having a positive cash-flow. Very few companies of this quality going this cheap. The placing was oversubscribed. Do your own research & see what we have here.